Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.
2015 United States Supreme Court case / From Wikipedia, the free encyclopedia
Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., 574 U.S. 318 (2015),[1] is a patent case of the Supreme Court of the United States regarding the Copaxone patent.[2][3] The Court held that, when reviewing a district court’s resolution of subsidiary factual matters made in the course of its construction of a patent claim, the Federal Circuit must apply a "clear error," not a de novo, standard of review.[2][3][1]
Quick Facts Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Argued October 15, 2014 Decided January 20, 2015 ...
Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. | |
---|---|
Argued October 15, 2014 Decided January 20, 2015 | |
Full case name | Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. |
Docket no. | 13-854 |
Citations | 574 U.S. 318 (more) |
Case history | |
Prior | 810 F. Supp. 2d 578 (S.D.N.Y. 2011); 876 F. Supp. 2d 295 (S.D.N.Y. 2012); affirmed in part, reversed in part, and remanded, 723 F.3d 1363 (Fed. Cir. 2013); stay denied, 572 U.S. 1301 (2014); cert. granted, 572 U.S. 1033 (2014) |
Subsequent | On remand, 789 F.3d 1335 (Fed. Cir. 2015) |
Holding | |
When reviewing a district court’s resolution of subsidiary factual matters made in the course of its construction of a patent claim, the Federal Circuit must apply a "clear error," not a de novo, standard of review. | |
Court membership | |
| |
Case opinions | |
Majority | Breyer, joined by Roberts, Scalia, Kennedy, Ginsburg, Sotomayor, Kagan |
Dissent | Thomas, joined by Alito |
Laws applied | |
F.R.C.P. 52(a)(6) |
Close